Drug intelligence / Profile preview

AVTF50X

Development stage: Preclinical
Lead developer: Aventi

Overview

AVTF50X is a preclinical-stage therapeutic candidate being developed by Aventi Biotechnology for the treatment of sarcopenia. It is characterized as a metabolite-based modality. Sarcopenia is a condition involving the progressive loss of skeletal muscle mass and strength, often associated with aging. As of early 2024, AVTF50X is in the preclinical phase of development, and its specific biological targets or mechanism of action have not been publicly disclosed by the developer.

Beyond the preview

Go deeper on AVTF50X.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AVTF50X.

Explore the full profile